What is the primary purpose of this 8-K/A filing?

This filing is an amendment to a previous 8-K to provide an update on the committee assignments for a newly appointed director, David S. Wichmann.

Which committees has David S. Wichmann been appointed to?

David S. Wichmann has been appointed to serve as a member of the Audit Committee and the Risk Committee.

When were these committee assignments made official?

The Board of Directors appointed Mr. Wichmann to these committees on July 28, 2021.

Why are the Audit and Risk Committees important for investors?

The Audit Committee plays a critical role in financial reporting integrity and oversight, while the Risk Committee focuses on the company's strategic risk management. Both are key areas of interest for investors concerned with corporate governance and long-term value.

BSX 8-K: Leadership Changes

Summary

This filing is an amendment to a previous 8-K regarding the appointment of David S. Wichmann to Boston Scientific Corporation's Board of Directors. While initially announced on June 23, 2021, this amendment clarifies his committee assignments. Investors will be interested to note that Mr. Wichmann has been appointed to serve as a member of both the Audit Committee and the Risk Committee, effective July 28, 2021. These committee roles are significant as they relate to financial oversight and strategic risk management, areas crucial for investor confidence and the company's long-term performance.

Key Highlights

1Amendment to a prior 8-K filing concerning director appointment.
2David S. Wichmann appointed to the Board of Directors on June 23, 2021 (as previously reported).
3Committee assignments for Mr. Wichmann were determined on July 28, 2021.
4Mr. Wichmann appointed as a member of the Audit Committee.
5Mr. Wichmann appointed as a member of the Risk Committee.

BOSTON SCIENTIFIC CORP 8-K/A Report, Executive Changes (Aug 2, 2021)

Summary

Key Highlights

Frequently Asked Questions